.jpg)
27°30′03″S 153°00′47″E / 27.500799°S 153.012925°E The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) was established in 2003. It is one of four stand-alone research institutions at the university with more than 500 researchers, students and support staff. The inaugural Director was Peter Gray[1] (2003 – 2015). The institute's second director, Professor Alan Rowan, commenced in 2016.
The AIBN is an integrated multi-disciplinary research institute bringing together researchers in the areas of bioengineering and nanotechnology. It is home to research groups working at the interface of the biological, chemical and physical sciences, and its applications in human health and environmental issues.
Notable work performed by the institute includes the needleless Nanopatch vaccine delivery device[2] that is ready to begin human trials;[3] local production of an experimental antibody for the treatment of the Hendra virus;[4] and biofuel research.[5]
- ^ "UQ appoints first director of new high-tech institute". The University of Queensland. The University of Queensland. Retrieved 15 September 2015.
- ^ Woolrich, Neal (16 September 2014). "Polio vaccine: Brisbane company Vaxxas teams up with WHO to trial Nanopatch needle-free delivery system". ABC Online. Retrieved 15 September 2015.
- ^ Branco, Jorge (11 February 2015). "Needle-less Nanopatch vaccine ready for human trials". Brisbane Times. Retrieved 15 September 2015.
- ^ "Experimental drug fast-tracked to fight Hendra outbreak". News.com.au. 31 May 2012. Retrieved 15 September 2015.
- ^ Hannam, Peter (22 May 2013). "Cost of biofuels no longer sky high". The Sydney Morning Herald. Retrieved 15 September 2015.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search